Loading…
Reported covered position: Congressional Science Fellow for Sen. Jon Tester (MT); Health Legislative Assistant for Sen. Sherrod Brown (OH)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Child Tax Credit for Pregnant Moms Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub.L.96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Out Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub.L.116-283).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · first_quarter · Q1
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub.L.96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Out Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub.L.116-283).
Source: Senate LDA
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access,non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
National Defense Authorization Act for Fiscal Year 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
National Defense Authorization Act for Fiscal Year 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations (no specific bills). Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access,non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
National Defense Authorization Act for Fiscal Year 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
National Defense Authorization Act for Fiscal Year 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations (no specific bills). Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access,non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access,non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Protecting Our Pharmaceutical Supply Chain from China Act of 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub. L. 116-283).
Protecting Our Pharmaceutical Supply Chain from China Act of 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
H.R. 1 - For the People Act of 2019
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019."
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019."
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019."
Interagency Pandemic Guidance for Consumers Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Accelerated Payments for Small Businesses Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
CLEAN Politics Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
CLEAN Politics Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2020 · fourth_quarter · Q4
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (Pub. L. 116-283).
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2020 · third_quarter · Q3
Value of Prescription Drugs, Senate & House. Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain management, S.3537 Protecting Our Pharmaceutical Supply Chain. Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Issues related to Medicare Part D policies, including patient access,non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2020 · second_quarter · Q2
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations (no specific bills). Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2020 · first_quarter · Q1
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · fourth_quarter · Q4
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019."
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · third_quarter · Q3
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · second_quarter · Q2
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · first_quarter · Q1
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues.
Biopharmaceutical innovation and patent policy issues.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · fourth_quarter · Q4
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Issues related to Medicare Part D policy (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · third_quarter · Q3
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Issues related to Medicare Part D policy (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · second_quarter · Q2
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · second_quarter · RA
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · first_quarter · Q1
Issues related to Medicare Part D policy (no specific bills).
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to importation (no specific bills).
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
H.R. 1 - For the People Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D policy (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE